Sanofi has announced that it will lower the list price of its insulin drug, Lantus, by 78 percent and will set a $35 cap on out-of-pocket costs for all patients.
The price change and cap will go into effect starting January 1, 2024. They follow a series of moves made last year to lower the price of diabetes medicine, including the launch of an unbranded version of Lantus and a $35 cap for uninsured patients.
Yet, Olivier Bogillot, head of U.S. general medicines at Sanofi, said "the health system was unable to take advantage of it due to its inherent structural challenges."
“Sanofi believes that no one should struggle to pay for their insulin and we are proud of our continued actions to improve access and affordability for millions of patients for many years," he said. "Our decision to cut the list price of our lead insulin needs to be coupled with broader change to the overall system to actually drive savings for patients at the pharmacy counter.”
Sanofi will also cut the price of short-acting Apidra by 70 percent.
Hoyt McGarity, CEO & President of 8AM Golf, joins Cheddar to discuss TGL and how the technology is changing the game of golf right before our eyes. Watch!
Amy Farley, Executive Editor at Fast Company, joins Cheddar to reveal how the Top 50 companies were chosen for a coveted spot on the list of Most Innovative.
Chris Versace, CIO at Tematica, discusses the fed decision, the current state of the market and how news in the coming days will tell us even more. Watch!
Olipop CEO, Ben Goodwin, joins Cheddar to discuss its recent $50M funding round and why other prebiotic soda company's successes is good for business. Watch!
The Knot Worldwide CEO Raina Moskowitz joins Cheddar to reveal the top wedding trends for 2025 and why some newlyweds-to-be want their big day to be phone free!
Shark Tank star Barbara Corcoran reveals how she is handling all of this recession news, the best time to buy a home and what she looks for when hiring. Watch!
